Your browser is no longer supported. Please, upgrade your browser.
AKRX Akorn, Inc. daily Stock Chart
AKRX [NASD]
Akorn, Inc.
Index- P/E- EPS (ttm)-3.16 Insider Own1.80% Shs Outstand127.65M Perf Week-51.38%
Market Cap12.87M Forward P/E0.46 EPS next Y0.20 Insider Trans1.35% Shs Float118.77M Perf Month-62.50%
Income-401.30M PEG- EPS next Q-0.05 Inst Own73.50% Short Float9.05% Perf Quarter-92.24%
Sales721.30M P/S0.02 EPS this Y44.30% Inst Trans6.50% Short Ratio0.79 Perf Half Y-97.55%
Book/sh-0.15 P/B- EPS next Y333.33% ROA-31.30% Target Price- Perf Year-97.69%
Cash/sh0.50 P/C0.18 EPS next 5Y- ROE-203.60% 52W Range0.17 - 5.46 Perf YTD-94.00%
Dividend- P/FCF- EPS past 5Y-35.65% ROI-11.80% 52W High-98.35% Beta1.13
Dividend %- Quick Ratio0.30 Sales past 5Y4.20% Gross Margin40.70% 52W Low-47.06% ATR0.05
Employees2227 Current Ratio0.50 Sales Q/Q23.40% Oper. Margin-51.20% RSI (14)27.63 Volatility38.15% 21.79%
OptionableYes Debt/Eq- EPS Q/Q-207.30% Profit Margin-55.60% Rel Volume2.44 Prev Close0.18
ShortableYes LT Debt/Eq- EarningsMar 05 BMO Payout- Avg Volume13.54M Price0.09
Recom3.00 SMA20-62.98% SMA50-70.41% SMA200-95.84% Volume32,988,850 Change-51.01%
Mar-20-19Initiated SunTrust Hold
Oct-17-18Upgrade Piper Jaffray Neutral → Overweight
Jul-25-18Reiterated RBC Capital Mkts Sector Perform $25 → $27
Apr-25-17Downgrade Piper Jaffray Overweight → Neutral
Apr-25-17Downgrade Jefferies Buy → Hold
Apr-25-17Downgrade Gabelli & Co Buy → Hold
Mar-10-17Reiterated WallachBeth Hold $22 → $25
Dec-01-16Initiated Goldman Sell
Nov-07-16Downgrade WallachBeth Buy → Hold $40 → $22
Nov-07-16Downgrade BofA/Merrill Buy → Underperform
Nov-04-16Downgrade RBC Capital Mkts Outperform → Sector Perform $37 → $24
Sep-15-16Upgrade Piper Jaffray Neutral → Overweight
Aug-05-16Reiterated WallachBeth Buy $39 → $40
Aug-05-16Downgrade Deutsche Bank Buy → Hold $33 → $33
Aug-02-16Downgrade Raymond James Outperform → Mkt Perform
Mar-18-16Reiterated Deutsche Bank Buy $40 → $33
Feb-12-16Reiterated RBC Capital Mkts Outperform $52 → $37
Dec-02-15Upgrade Nomura Neutral → Buy
Sep-29-15Initiated Nomura Neutral
Sep-09-15Initiated JMP Securities Mkt Perform
May-28-20 11:14AM  WeWork Board Factions Head for Clash Over New Directors Bloomberg
May-26-20 12:42PM  Akorn, Inc. -- Moody's downgrades Akorn's PDR to D-PD following Chapter 11 filing Moody's +21.86%
May-22-20 01:37PM  Akorn Seeks Bankruptcy After Failed Takeover, FDA Warnings Bloomberg -7.08%
May-21-20 12:21PM  Akorn Files Chapter 11 After Failure to Be Acquired TheStreet.com -33.87%
08:01AM  The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive Benzinga
07:56AM  Akorn Plummets 27% In Pre-Market On Bankruptcy Filing SmarterAnalyst
May-20-20 11:52PM  Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success PR Newswire
08:12PM  Forescout sues Advent to complete $1.9 billion merger Reuters
May-11-20 05:14PM  Akorn Provides First Quarter 2020 Results GlobeNewswire
Apr-27-20 06:17PM  Enphase Energy and Paylocity Set to Join S&P MidCap 400; Core Laboratories and Meredith to Join S&P SmallCap 600 PR Newswire
Apr-07-20 02:08PM  WeWork Directors Sue SoftBank Over Decision to Abandon Deal Bloomberg
Apr-02-20 03:59PM  Bed Bath sues 1-800-Flowers for trying to renege on deal over COVID-19 Reuters +5.37%
Apr-01-20 06:20AM  Akorn Provides Update on Sale Process PR Newswire -64.49%
Feb-29-20 07:20AM  US$4.00: That's What Analysts Think Akorn, Inc. Is Worth After Its Latest Results Simply Wall St.
Feb-26-20 04:58PM  Akorn Provides Fourth Quarter and Full Year 2019 Results GlobeNewswire -5.26%
Feb-19-20 09:55AM  Akorn (AKRX) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-12-20 05:29PM  Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business PR Newswire
Feb-10-20 07:00AM  Akorn Continues Negotiations with Lenders PR Newswire -6.40%
Jan-31-20 07:12AM  How Many Akorn, Inc. (NASDAQ:AKRX) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Jan-14-20 12:41PM  Akorn, Inc. -- Moody's announces completion of a periodic review of ratings of Akorn, Inc. Moody's -7.84%
Dec-19-19 09:26AM  Akorn Enters Oversold Territory Zacks -11.87%
Dec-18-19 02:52PM  Akorn's stock extends plunge toward record low after disclosing it was exploring a bankruptcy MarketWatch -27.72%
Dec-16-19 07:51AM  Akorn Announces Extension of Standstill Agreement GlobeNewswire -6.65%
Dec-11-19 01:54PM  Is Akorn, Inc. (AKRX) Going To Burn These Hedge Funds ? Insider Monkey
Dec-02-19 08:00AM  Easy Come, Easy Go: How Akorn (NASDAQ:AKRX) Shareholders Got Unlucky And Saw 90% Of Their Cash Evaporate Simply Wall St.
Nov-28-19 09:00AM  Akorn (AKRX) Moves to Strong Buy: Rationale Behind the Upgrade Zacks
Nov-26-19 08:36AM  Generic Drugmakers Gain as Price-Fixing Probe Nears an End Zacks -8.23%
Nov-19-19 04:54PM  Teva, Bausch Could Be Next to File for Bankruptcy GuruFocus.com
Nov-12-19 08:27AM  The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's, Akorn and Quanex Zacks
Nov-11-19 07:03AM  5 Small-Cap Stocks Outpacing the Broader Market in 2019 Zacks -5.26%
Nov-07-19 08:22AM  New Strong Buy Stocks for November 7th Zacks
Nov-05-19 07:00PM  Akorn to Present at the Credit Suisse Healthcare Conference GlobeNewswire
Nov-02-19 05:22AM  Edited Transcript of AKRX earnings conference call or presentation 31-Oct-19 2:00pm GMT Thomson Reuters StreetEvents
Oct-31-19 08:35AM  Akorn (AKRX) Q3 Earnings and Revenues Top Estimates Zacks
07:00AM  Akorn Provides Preliminary Third Quarter 2019 Results GlobeNewswire
Oct-24-19 10:32AM  Will Akorn (AKRX) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-17-19 09:00AM  All You Need to Know About Akorn (AKRX) Rating Upgrade to Buy Zacks +13.80%
Oct-15-19 07:50AM  The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings Benzinga +6.97%
Oct-14-19 04:25PM  Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05% GlobeNewswire
01:05PM  Akorn to Report Third Quarter 2019 Financial Results and Host Conference Call GlobeNewswire
Sep-29-19 08:36AM  Should You Be Concerned About Akorn, Inc.'s (NASDAQ:AKRX) Historical Volatility? Simply Wall St.
Aug-26-19 01:35PM  Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15% GlobeNewswire +8.52%
Aug-14-19 03:30PM  Is Akorn (NASDAQ:AKRX) A Risky Investment? Simply Wall St. -7.12%
Aug-07-19 10:30PM  Edited Transcript of AKRX earnings conference call or presentation 1-Aug-19 1:00pm GMT Thomson Reuters StreetEvents
Aug-02-19 07:24AM  Akorn (AKRX) Q2 2019 Earnings Call Transcript Motley Fool -5.22%
Aug-01-19 08:55AM  Akorn (AKRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
Jul-29-19 11:33AM  Penny Stocks to Buy Using Technical Analysis for August 2019 Investopedia
Jul-25-19 10:33AM  Analysts Estimate Akorn (AKRX) to Report a Decline in Earnings: What to Look Out for Zacks -6.78%
Jul-11-19 04:32PM  Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call GlobeNewswire -5.57%
Jun-28-19 07:00AM  Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5% GlobeNewswire
Jun-27-19 11:20AM  Did Hedge Funds Drop The Ball On Akorn, Inc. (AKRX) ? Insider Monkey +7.29%
Jun-25-19 11:00AM  Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues Benzinga
10:32AM  Akorn gets FDA warning letter for another manufacturing plant Reuters
09:41AM  Akorn Files Complaint on Fresenius' Canceled Bid Investopedia
08:17AM  Drugmaker Akorn Receives FDA Warning Letter Regarding N.J. Facility TheStreet.com
08:08AM  UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant Reuters
07:44AM  Generics maker Akorn receives warning letter from the FDA relating to NJ facility MarketWatch
07:35AM  Akorn Receives FDA Warning Letter GlobeNewswire
Jun-14-19 07:01AM  How Many Akorn, Inc. (NASDAQ:AKRX) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
May-30-19 07:59AM  Akorn to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-21-19 07:40AM  The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails Benzinga +5.02%
May-20-19 04:05PM  Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1% GlobeNewswire
08:01AM  Akorn to Present at the RBC Capital Markets Healthcare Conference GlobeNewswire
May-16-19 01:08AM  Edited Transcript of AKRX earnings conference call or presentation 7-May-19 2:00pm GMT Thomson Reuters StreetEvents
May-12-19 09:49PM  Heres What Hedge Funds Think About Akorn, Inc. (AKRX) Insider Monkey
May-08-19 09:24AM  Akorn (AKRX) Q1 2019 Earnings Call Transcript Motley Fool +29.58%
May-07-19 08:35AM  Akorn (AKRX) Reports Q1 Loss, Tops Revenue Estimates Zacks +17.16%
07:24AM  Akorn: 1Q Earnings Snapshot Associated Press
07:05AM  Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance GlobeNewswire
Apr-24-19 09:14AM  Introducing Akorn (NASDAQ:AKRX), The Stock That Tanked 89% Simply Wall St.
Apr-22-19 07:00PM  Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX) Business Wire +7.94%
03:00PM  FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
02:27PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc. GlobeNewswire
12:58PM  Here's Why Akorn Stock Rose as Much as 14.4% Today Motley Fool
11:09AM  DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:58AM  FINAL DEADLINE - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:28AM  Akorn Receives 2 Generic Nose Spray Approvals Benzinga
Apr-19-19 06:00PM  3-Day Deadline Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
05:36PM  Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI GlobeNewswire
Apr-18-19 05:00PM  Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5% GlobeNewswire -5.14%
04:05PM  Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) GlobeNewswire
01:47PM  APRIL 22 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Akorn, Inc. AKRX GlobeNewswire
01:40PM  4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:51AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX GlobeNewswire
10:57AM  AKRX, HIIQ & AMRN - Class Action Deadline Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-17-19 08:41PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc. GlobeNewswire -5.50%
Apr-16-19 04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX ACCESSWIRE
10:57AM  AKRX, HIIQ & AMRN - Class Action Notice Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-15-19 05:31PM  AKORN APRIL 22nd DEADLINE: Rosen Law Firm Reminds Akorn, Inc. Investors of Important Deadline in Securities Class Action Lawsuit Filed by the Firm AKRX GlobeNewswire
01:56PM  Akorn to Report First Quarter 2019 Financial Results and Host Conference Call GlobeNewswire
10:20AM  Block & Leviton LLP Reminds Shareholders of Important Deadlines: TAP, AKRX, SYNH, CTL GlobeNewswire
08:45AM  Options Traders Expect Huge Moves in Akorn (AKRX) Stock Zacks
Apr-12-19 03:30PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm ACCESSWIRE
03:00PM  AKRX, HIIQ & AMRN - Class Action Reminder Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
09:55AM  AKRX, HIIQ & AMRN - Class Action Update Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-11-19 03:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX ACCESSWIRE
Apr-10-19 10:21PM  AKRX ALERT: Zhang Investor Law Reminds Investors of April 22 Deadline in Securities Class Action Lawsuit Against Akorn, Inc. AKRX GlobeNewswire
Apr-09-19 08:31PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline - AKRX PR Newswire
10:48AM  Class Action Reminder - AKRX, HIIQ & AMRN Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-08-19 05:27PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In AKRX, UMC, CAG or CNDT To Contact The Firm GlobeNewswire
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young ChristopherEVP, Global OperationsMar 13Sale0.5654,62930,59269,273Mar 13 08:49 PM
Kafer JonathanEVP & Chief Commercial OfficerMar 06Sale1.0211,08811,310193,257Mar 10 09:25 PM
MEYER STEVEN JDirectorMar 03Buy0.9915,00014,850145,225Mar 04 06:39 PM
MEYER STEVEN JDirectorMar 02Buy1.0885,00091,800130,225Mar 04 06:39 PM
MEYER STEVEN JDirectorAug 15Buy2.5010,00025,000183,154Aug 15 03:56 PM
MEYER STEVEN JDirectorAug 14Buy2.7010,00027,000173,154Aug 15 03:56 PM
WEINSTEIN ALAN DDirectorMay 31Buy3.9750,000198,500161,555Jun 04 04:22 PM